COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

Homologous recombination (HR)-defective cells, such as those lacking BRCA1/2, are hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition. However, BRCA-deficient tumors represent only a small fraction of adult cancers, potentially restricting the therapeutic utility of PARP inhibitor monot...

Full description

Bibliographic Details
Main Authors:	Johnson, Neil, Li, Yu-Chen, Walton, Zandra E., Cheng, Katherine A., Li, Danan, Rodig, Scott J., Moreau, Lisa A., Unitt, Christine, Bronson, Roderick T., Thomas, Huw D., Newell, David R., D’Andrea, Alan D., Curtin, Nicola J., Wong, Kwok-Kin, Shapiro, Geoffrey I.
Format:	Online
Language:	English
Published:	2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272302/

Similar Items

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
by: Zhu, Qing, et al.
Published: (2015)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
by: Ding, Xia, et al.
Published: (2016)

p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells
by: Brugarolas, James, et al.
Published: (1998)

The role of PARP in DNA repair and its therapeutic exploitation
by: Javle, M, et al.
Published: (2011)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
by: O’Sullivan, Ciara C., et al.
Published: (2014)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
by: Znojek, P, et al.
Published: (2014)

Visualization of a DNA-PK/PARP1 complex
by: Spagnolo, Laura, et al.
Published: (2012)

PARty promoters: Hormone-dependent gene regulation requires CDK2 activation of PARP1
by: Wright, Roni H.G., et al.
Published: (2012)

Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
by: McCrudden, Cian M., et al.
Published: (2015)

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
by: De Soto, Joseph A., et al.
Published: (2006)

PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer
by: Hay, T, et al.
Published: (2008)

Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2
by: Arbini, A A, et al.
Published: (2013)

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
by: Joseph A. De Soto, Chu-Xia Deng
Published: (2006-01-01)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
by: Konecny, G E, et al.
Published: (2016)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
by: Luo, Jiayan, et al.
Published: (2016)

Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
by: Yamamoto, Kimiyo N., et al.
Published: (2014)

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
by: Sun, Chong-kui, et al.
Published: (2014)

Predicting PARP inhibitor sensitivity and resistance
by: Bebb, D. Gwyn, et al.
Published: (2012)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
by: Herriott, Ashleigh, et al.
Published: (2015)

MERCOSUR: INTEGRATION COMPROMISE OF THE SOUTH
by: D. V. Koshkul
Published: (2015-01-01)

PARP inhibitors
by: Anwar, Maheen, et al.
Published: (2015)

An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells
by: Muñoz, Meilen C., et al.
Published: (2014)

Compromise
Published: (1968)

Structural Implications for Selective Targeting of PARPs
by: Steffen, Jamin D., et al.
Published: (2013)

ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells
by: Roper, Stephen J., et al.
Published: (2014)

Aag DNA Glycosylase Promotes Alkylation-Induced Tissue Damage Mediated by Parp1
by: Calvo, Jennifer A., et al.
Published: (2013)

Development of CDK inhibitors as cancer therapeutics
by: Lane, D
Published: (2005)

Compromise is so … compromised: Goldilocks, go home
by: Morris B., Holbrook
Published: (2008)

Pragmalinguistic Differences between Proficient and Less Proficient Malay Learners of English in Request
by: Ernisa, Marzuki, et al.
Published: (2009)

Reading Comprehension Strategies and Comprehension Level of Proficient and Low Proficient ESL Readers
by: Danga, Hawa Abdullai Morjan
Published: (1999)

Cyclin K goes with Cdk12 and Cdk13
by: Kohoutek, Jiri, et al.
Published: (2012)

PARP inhibitors are not all equal
by: Dent, Paul
Published: (2013)

PARP inhibitors: the race is on
by: Brown, Jessica S, et al.
Published: (2016)

PARP inhibitors in ovarian cancer
by: Cibula, David, et al.
Published: (2015)

Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
by: Gareth Evans, D, et al.
Published: (2004)

Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients
by: Kim, Kyoung Min, et al.
Published: (2016)

Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients1
by: Park, See-Hyoung, et al.
Published: (2015)

DNA-dependent SUMO modification of PARP-1☆
by: Zilio, Nicola, et al.
Published: (2013)

Boost your English proficiency
by: The Star,
Published: (2012)

Boosting English language proficiency
by: Chin, Mary
Published: (2018)